Skip to main content
SpringerLink
Log in
Book cover

Obesity pp 117–130Cite as

Obesity and Diabetes

  • Chapter

Abstract

It is well-known that a tight association prevails between obesity and diabetes. In the past only diabetes was considered as a disease but now they both are called disease. Although it is difficult to come to an accurate figure, according to estimation there are around 300 million diabetes patients in the world. Furthermore, as it is suggested that at any one time only about 50 % of the diabetes sufferers are diagnosed and if so it can be estimated that realistically there are around 600 million diabetes patients in the world. Additionally due to longevity in ageing and an increase in obesity, the situation in the future is expected to be alarming.

Now if we look at the prevalence of overweight people there are around 1.9 billion of them out of which around 600 million are obese. If we sum up these two figures (i.e. patients suffering from diabetes and patients suffering from obesity) it can be said that globally there are about 1.2 billion people suffering from these two kith and kin diseases. The phrase kith and kin used here because biologically they are closely related and obesity plays a major role to give rise to diabetes. Combined together, these two diseases must be on the top of the list of all other disease related human suffering.

It is an irony that that by majority of the population these two ailments are neither considered as disease nor taken up seriously against it, causing a large number of complications including certain fatal outcomes such as cardiovascular diseases including atherosclerosis (causing angina, heart attack and stroke) and congenital heart disease, nephropathy or kidney damage and pancreatic cancer. A number of other non-fatal complications include retinopathy or blindness, impairment of immune systems causing autonomic and somatic neuropathy, periodontal disease, erectile dysfunction, foot amputation due to gangrene caused by microbial infection, significant reduction in immune system leading to reduced ability of wound healing, depression etc. If we count the number of metabolic syndrome (see below) caused by obesity they are too many including the fatal ones.

This chapter addresses these two diseases in some details and more importantly provides the messages to the patients that, considering the vast number of complications emerging through these two diseases, these ailments must not be taken easily and should be given high priority to minimise or eliminate them, so that they can enjoy relatively healthy life. Failing that they may be subject to attack by one more of these complications leading to significantly reducing the quality of life or even premature death.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Maraschin Jde F. Classification of diabetes. Adv Exp Med Biol. 2012;771:12–9.

    PubMed  Google Scholar 

  2. George AM, Jacob AG, Fogelfeld L. Lean diabetes mellitus: an emerging entity in the area of obesity. World J Diabetes. 2015;6(4):613–20.

    PubMed Central  PubMed  Google Scholar 

  3. Monaghan M, Helgeson V, Wiebe D. Type 1 diabetes in young adulthood. Curr Diabetes Rev. 2015;11(4):239–50.

    Article  PubMed  Google Scholar 

  4. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol. 2012;771:42–50.

    PubMed  Google Scholar 

  5. Ahmad SI, Imam K. Diabetes, a comprehensive treatise for patients and caregivers. VADEMECUM, Landes Bioscience, Austin, Texas 78701, USA;2014, ISBN 978-1-57059-775-6.

    Google Scholar 

  6. Centre for Disease Control and Prevention. National diabetic fact sheet, 2011 extracted from Google.

    Google Scholar 

  7. Chaudhary SB. GULF news report, diabetes growing rapidly in GCC region, 13 Nov 2014.

    Google Scholar 

  8. Ahmad SI. Diabetes, an old disease a new insight. Springer Science+Business Media LLC, New York, USA, 2012, ISBN 978-1-4614-5440-3.

    Google Scholar 

  9. Basdevant A, Ciangura C. Obesity, a disease. Bull Acad Natl Med. 2010;194(1):13–20.

    PubMed  Google Scholar 

  10. Obesity and overweight, WHO fact sheet No 311, Updated January 2015. Google’s presentation.

    Google Scholar 

  11. Hebert JR, Allison DB, Archer E, et al. Scientific decision making, policy decision, and the obesity pandemic. Mayo Clinic Proc. 2013;88(6):593–604.

    Article  Google Scholar 

  12. Popkin BM, Adair LS, Ng SW. Global nutrition transition and pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3–21.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Flatt JP. Misconception in body weight regulation: implications for the obesity pandemic. Crit Rev Clin Lab Sci. 2012;49(4):150–65.

    Article  CAS  PubMed  Google Scholar 

  14. Bonomini F, Rodella LF, Rezzani R. Metabolic syndrome, ageing and involvement of oxidative stress. Aging Dis. 2015;6(2):109–20.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Rochalini Y, Pothineni NV, Mehta JL. Metabolic syndrome: does it differ between women and men? Cardiovasc Drugs Ther 2015;29(4):329–38.

    Article  Google Scholar 

  16. Gallagher EJ, Leroith D, Karnieli E. The metabolic syndrome – from insulin resistance to obesity and diabetes. Med Clin North Am. 2011;95(5):855–73.

    Article  CAS  PubMed  Google Scholar 

  17. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi:10.1155/2014/943162. Epub 2014 214 March 11.

    PubMed Central  PubMed  Google Scholar 

  18. Peirson L, Fitzpatrick-Lewis D, Morrison K, et al. Treatment of overweight and obesity in children and youth: a systemic review and meta-analysis. CMAJ Open. 2015;3(1):E35–46.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Sanders RH, Han A, Baker JS, et al. Childhood obesity and its physical and psychological co-morbidities: a systemic review of Australian children and adolescent. Eur J Pediatr. 2015;174(6):715–46.

    Article  PubMed  Google Scholar 

  20. Onge ES, Miller SA, Motycka C, et al. A review of the treatment of type 2 diabetes in children. J Pediatr Pharmacol Ther. 2015;20(1):4–16.

    PubMed Central  PubMed  Google Scholar 

  21. Johnson 3rd JA, Johnson AM. Urban-rural differences in childhood and adolescent obesity in the United States: a systemic review and meta-analysis. Child Obes. 2015;11(3):233–41.

    PubMed  Google Scholar 

  22. Vague J, Vague P, Tramoni M, et al. Clinical features of diabetogenic and atherogenic obesity. Tohoku J Exp Med. 1983;141(Suppl):147–59.

    Article  PubMed  Google Scholar 

  23. Soumaya K. Molecular mechanism of insulin resistance. Adv Exp Med Biol. 2012;771:240–51.

    PubMed  Google Scholar 

  24. Kapeller R, Moriarty A, Strauss A, et al. Tyrosine phosphorylation of tub and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signalling by insulin. J Biol Chem. 1999;274:24980–6.

    Article  CAS  PubMed  Google Scholar 

  25. Sato M, Ozawa T, Yoshida T, et al. A fluorescent indicator for tyrosine phosphorylation-based insulin signalling pathways. Anal Chem. 1999;71:3948–54.

    Article  CAS  PubMed  Google Scholar 

  26. Sale EM, Sale GJ. Protein kinase B: signalling roles and therapeutic targeting. Cell Mol Life Sci. 2008;65:113–27.

    Article  CAS  PubMed  Google Scholar 

  27. Sano H, Eguez L, Teruel MN, et al. Rab 10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab. 2007;5:293–303.

    Article  CAS  PubMed  Google Scholar 

  28. Sano N, Kane S, Sano E, et al. Insulin stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem. 2003;278:14599–602.

    Article  CAS  PubMed  Google Scholar 

  29. Kim YB, Nikoulina SE, Ciaraldi TP, et al. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositol 3-kinase, in muscle in type 2 diabetes. J Clin Invest. 1999;104:733–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Frojdo S, Durand C, Molin L, et al. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signalling pathway by SIRTI1. Mol Cell Endocrinol. 2011;335:166–76.

    Article  PubMed  Google Scholar 

  31. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63(4):250–9.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38(3):183–91.

    Article  CAS  PubMed  Google Scholar 

  33. Gerner RR, Weiser V, Moschen AR, et al. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Can J Physiol Pharmacol. 2013;91(11):867–72.

    Article  CAS  PubMed  Google Scholar 

  34. Proenca AR, Sertie RA, Oliviera AC. New concept in white adipose tissue physiology. Braz J Med Biol Res. 2014;47(3):192–205.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Takada J, Fonseca-Alaniz MH, de Campos TB, et al. Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes. J Endocrinol. 2008;198:51–60.

    Article  CAS  PubMed  Google Scholar 

  36. Azuma K, Heilbronn LK, Albu JB, et al. Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2007;293:E435–42.

    Article  CAS  PubMed  Google Scholar 

  37. Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J Physiol. 2012;590(pt 8):1787–801.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Dunmore SJ, Brown JE. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrionl. 2013;216(1):T37–45.

    Article  CAS  Google Scholar 

  39. Oelkrug R, Polymeropoulos ET, Jastroch M. Brown adipose tissue: physiological function and evolutionary significance. J Comp Physiol B. 2015;185(6):587–606.

    Article  CAS  PubMed  Google Scholar 

  40. Balsan GA, Vieira JL, Oliviera AM, et al. Relationship between adiponectin, obesity and insulin resistance. Rev Assoc Med Bras. 2015;61(1):72–80.

    Article  PubMed  Google Scholar 

  41. Moschen AR, Wiesser V, Tilg H. Adiponectin: key player in the adipose tissue-liver crosstalk. Curr Med Chem. 2012;19(32):5467–73.

    Article  CAS  PubMed  Google Scholar 

  42. Procaccini C, Pucino, V, Mantzoros CS, et al. Leptin in autoimmune diseases. Metabolism. 2015;64(1):92–104. Mohammad S. Role of free fatty acid receptor 2 (FFAR2) in the regulation of metabolic homeostasis. Curr Drug Targets. 2015. [Epub ahead of print].

    Google Scholar 

  43. Hara T, Kashihara D, Ichimura A. Role of free fatty acid receptors in the regulation of energy metabolism. Biochim Biophys Acta. 2014;1841(9):1292–300.

    Article  CAS  PubMed  Google Scholar 

  44. Bowden G. Obesity and free fatty acid. Endocrinol Metab Clin North Am. 2008;37(3):635–46.

    Article  Google Scholar 

  45. Sato T, Ida T, Nakamura Y, et al. Physiological roles of ghrelin in obesity. Obes Res Clin Pract. 2014;8(5):e405–13.

    Article  PubMed  Google Scholar 

  46. Massadi OA, Lopez M, Ferno J, et al. What is the real relevance of endogenous ghrelin? Peptides. 2015;70:1–6. pii: SO196-9781(15)00148-5. doi:10.1016/j.peptides.2015.04.027.

    Google Scholar 

  47. Gesmundo I, Gallo D, Favaro E, et al. Obestatin: a new metabolic player in the pancreas and white adipose tissue. IUBMB Life. 2013;65(12):976–82.

    Article  CAS  PubMed  Google Scholar 

  48. Su XJ, Dong RX, Li YP, et al. Obestatin and cardiovascular health. Peptides. 2014;52:58–60.

    Article  CAS  PubMed  Google Scholar 

  49. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res. 2012;44(1):6–14.

    Article  CAS  PubMed  Google Scholar 

  50. Fedders R, Muenzner M, Schupp M. Retinol binding protein 4 and its membrane receptors: a metabolic perspective. Horm Mol Biol Clin Investig. 2015;22(1):27–37. Pii: /j/hmbci.ahead-of-print/hmbci-2015-0013/hmbci-2015-0013.xml. doi:10.1515/hmbci-2015-0013.

  51. Ramirez Alvarado MM, Sanchez RC. Tumor necrosis factor-α, insulin resistance, the lipoprotein metabolism and obesity in humans. Nutr Hosp. 2012;27(6):1751–7.

    PubMed  Google Scholar 

  52. Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208–19.

    Article  CAS  PubMed  Google Scholar 

  53. Jankun J, Al-Senaidy A, Skrzypczak-Jankun E. Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review). Int J Mol Med. 2012;29(1):3–11.

    CAS  PubMed  Google Scholar 

  54. Ahren B. Glucagon – early breakthroughs and recent discoveries. Peptides. 2015;67:74–81.

    Article  CAS  PubMed  Google Scholar 

  55. Campbell JE, Drucker DJ. Islet α cells and glucagon-critical regulator of energy homeostasis. Nat Rev Endocrinol. 2015;11(6):329–38.

    Article  CAS  PubMed  Google Scholar 

  56. Ye J. Mechanism of insulin resistance in obesity. Front Med. 2013;7(1):14–24.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Ohta Y, Tanizawa Y. Insulin secretion and insulin resistance. Nihon Rinsho. 2013;71(11):1936–40.

    PubMed  Google Scholar 

  58. Li Y, Ding L, Hassan W, et al. Adipokines and hepatic insulin resistance. J Diabetes Res. 2013;2013:170532. doi:10.1155/2013/170532. Epub 2013 May 16.

    PubMed Central  PubMed  Google Scholar 

  59. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587–91.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Molereau B, Manie S, Napoletano F. Getting the better of ER stress. J Cell Commun Signal. 2014;8(4):311–21.

    Article  Google Scholar 

  61. Khan S, Wang CH. ER stress in adipocytes and insulin resistance: mechanism and significance (review). Mol Med Rep. 2014;10(5):2234–40.

    CAS  PubMed  Google Scholar 

  62. Biden TJ, Boslem E, Chu KY. Lypotoxic endoplasmic reticulum stress, β cell failure, and type 2 diabetes mellitus. Trends Endocrinol Metab. 2014;25(8):389–98.

    Article  CAS  PubMed  Google Scholar 

  63. Engin F, Eguyen T, Yermalovich A. Aberrant islet unfolded protein response in type 2 diabetes. Sci Rep. 2014;4:4054.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Huang L, Xie H, Liu H. Endoplasmic reticulum stress, diabetes mellitus, and tissue injury. Curr Protein Pept Sci. 2014;15(8):812–8.

    Article  CAS  PubMed  Google Scholar 

  65. Sun J, Cui J, He Q. Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Mol Aspects Med. 2015;42:105–18.

    Article  CAS  PubMed  Google Scholar 

  66. Liu M, Chen H, Wei L et al. Endoplasmic reticulum (ER) localization is critical for DsbA-L protein to suppress ER stress and adiponectin down regulation in adipocytes. J Biol Chem 2015;290(16):10143–8.

    Article  CAS  PubMed  Google Scholar 

  67. Chaudhari N, Talwar P, Parimasetty A, et al. A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci. 2014;8:213. doi:10.3389/fncel.2014.00213. eCollection 2014.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, UK

    Shamim I. Ahmad MD

Authors
  1. Shamim I. Ahmad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shamim I. Ahmad MD .

Editor information

Editors and Affiliations

  1. School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom

    Shamim I. Ahmad

  2. Al Mouwasat Hospital, Jubail, Saudi Arabia

    Syed Khalid Imam

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ahmad, S.I. (2016). Obesity and Diabetes. In: Ahmad, S., Imam, S. (eds) Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-19821-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19821-7_9

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19820-0

  • Online ISBN: 978-3-319-19821-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation